Actinium Pharmaceuticals, Inc. (ATNM) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Actinium Pharmaceuticals reported revenue of $90,000. Net income was -$33.9M (a -37652.2% net margin), or -$1.09 per diluted share. Operating margin was -40274.4%. Operating activities generated -$24.6M of cash, leaving -$24.7M of free cash flow. At fiscal year end, Actinium Pharmaceuticals held $51.8M in total assets against $43.9M in total liabilities, including $48.0M of cash and equivalents.
Open the full interactive Actinium Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Actinium Pharmaceuticals Key Stats
| Share Price | $1.00 |
|---|---|
| Market Cap | $31.4M |
| 52-Week Range | $0.75 – $1.69 |
| Shares Outstanding | 31.4 million (basic, 2026 Q2) |
Actinium Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $1.1M | $1.0M | $81,000 | — | $90,000 |
| Gross Profit | — | $244,000 | — | — | — | — |
| Operating Income | -$22.4M | -$25.0M | -$34.1M | -$51.9M | -$42.1M | -$36.2M |
| Pre-Tax Income | -$22.2M | -$24.8M | -$33.0M | -$48.8M | -$38.2M | -$33.9M |
| Net Income | -$22.2M | -$24.8M | -$33.0M | -$48.8M | -$38.2M | -$33.9M |
| Diluted EPS | -$1.83 | -$1.20 | -$1.37 | -$1.83 | -$1.27 | -$1.09 |
Actinium Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $90,000 | — | — | $35.0M |
| Net Income | -$5.1M | -$5.9M | -$5.5M | $27.9M |
| Diluted EPS | -$0.16 | -$0.19 | -$0.18 | $0.89 |
Actinium Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $63.6M | $77.8M | $108.9M | $76.7M | $72.9M | $48.0M |
| Current Assets | $64.9M | $79.7M | $110.9M | $78.3M | $74.5M | $49.4M |
| Total Assets | $66.4M | $80.4M | $114.2M | $81.4M | $76.9M | $51.8M |
| Current Liabilities | $4.8M | $6.8M | $10.6M | $8.5M | $8.1M | $8.0M |
| Total Liabilities | $5.1M | $6.8M | $47.7M | $45.1M | $44.1M | $43.9M |
| Shareholders' Equity | $61.3M | $73.5M | $66.5M | $36.4M | $32.8M | $7.8M |
Actinium Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$21.6M | -$20.9M | $8.6M | -$47.3M | -$33.1M | -$24.6M |
| Cash From Investing | -$253,000 | -$133,000 | -$366,000 | -$153,000 | -$11,000 | -$104,000 |
| Cash From Financing | $76.2M | $35.2M | $23.1M | $14.9M | $29.3M | -$217,000 |
| Free Cash Flow | -$21.9M | -$21.0M | $8.3M | -$47.5M | -$33.1M | -$24.7M |
Figures from Actinium Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Actinium Pharmaceuticals financials page for every line item.
Actinium Pharmaceuticals Company Profile
| Ticker | ATNM |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001388320 |
Frequently Asked Questions
What was Actinium Pharmaceuticals' revenue in fiscal 2025?
Actinium Pharmaceuticals (ATNM) reported revenue of $90,000 for fiscal 2025.
What is Actinium Pharmaceuticals' annual revenue history?
Actinium Pharmaceuticals' annual revenue by fiscal year: 2021: $1.1M; 2022: $1.0M; 2023: $81,000; 2025: $90,000.
What was Actinium Pharmaceuticals' net income in fiscal 2025?
Actinium Pharmaceuticals reported net income of -$33.9M for fiscal 2025.
What was Actinium Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Actinium Pharmaceuticals' diluted EPS was -$1.09 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Actinium Pharmaceuticals generate in fiscal 2025?
Actinium Pharmaceuticals generated -$24.7M of free cash flow in fiscal 2025.
What was Actinium Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Actinium Pharmaceuticals reported revenue of $35.0M.
How many shares of Actinium Pharmaceuticals are outstanding?
Actinium Pharmaceuticals reported a weighted average of 31.4 million basic shares outstanding in 2026 Q2.
What is Actinium Pharmaceuticals' market cap?
Based on its latest closing price, Actinium Pharmaceuticals (ATNM) has a market capitalization of about $31.4M.
When does Actinium Pharmaceuticals' fiscal year end?
Actinium Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Actinium Pharmaceuticals headquartered?
Actinium Pharmaceuticals lists its business address in New York, New York in its SEC filings.